🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

U.S. hospitals urge DOJ antitrust probe of Anthem-Cigna deal

Published 08/06/2015, 03:47 PM
© Reuters. Cigna CEO David Cordani is interviewed at Reuters Health Summit 2014 in Washington
CI
-
ELV
-
AET
-
HUM
-
SYY
-

By Caroline Humer

NEW YORK (Reuters) - U.S. hospitals urged antitrust regulators this week to consider whether health insurer Anthem Inc's (N:ANTM) planned acquisition of rival Cigna Corp (N:CI) would boost healthcare costs.

In a letter to the Department of Justice, the hospital industry's largest lobbying group said combining the No. 1 and No. 5 health insurers threatens to reduce competition in 817 geographic markets serving 45 million consumers.

In many of those markets, the American Hospital Association said, there are no strong competitors to buy assets that Anthem or Cigna might want to sell to pass muster with federal authorities. State insurance regulators will also look at the deal.

A Cigna spokesman did not have an immediate comment.

Anthem said in an emailed statement that it plans to meet with stakeholders, including hospitals. "Our commitment to ensuring consumers have access to affordable health coverage and quality care is the foundation of the proposed transaction," the statement said.

On July 24, Anthem announced plans to buy Cigna for $47 billion, just weeks after Aetna Inc (N:AET) inked an agreement with Humana Inc (N:HUM). The deals will reduce the number of national insurers to three from five.

Anthem and Cigna have said they expect the deal to pass antitrust scrutiny and they have considered where asset sales might be needed.

The hospital association said in the letter dated Aug. 5 that it doubted Anthem and Cigna would find a suitable buyer for assets that provide insurance plans to millions of customers, also known as covered lives.

"In the 817 at-risk markets, over half the lives that need to be divested reside across 368 (metro regions) and rural counties with no divestiture possibility," the group wrote.

Anthem and Cigna may need to divest from 2.9 million to 3.7 million covered lives in the commercial business to preserve competition in those markets, it said, and 1.7 million to 2 million of those are in markets with no suitable acquirer. The analysis was based on the Herfindahl-Hirschman Index that measures market concentration.

In the commercial self-funded insurance business, where employers pay Anthem and Cigna to manage benefits, 4.4 million to 4.7 million covered lives may need to be sold, and there is no satisfactory acquirer for 2.8 million to 3 million lives, the letter said.

© Reuters. Cigna CEO David Cordani is interviewed at Reuters Health Summit 2014 in Washington

The hospitals also urged the DOJ to look at the reduced competition in the market for national customers, citing the Federal Trade Commission case against Sysco Corp (NYSE:SYY)., which the FTC won.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.